Results 261 to 270 of about 41,938 (307)

Immunotherapeutic perspective for bispecific antibodies

Immunology Today, 2000
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
A B, van Spriel, H H, van Ojik, J G, van De Winkel   +2 more
openaire   +2 more sources

Catumaxomab: A bispecific trifunctional antibody

Drugs of Today, 2009
The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
M, Sebastian, A, Kuemmel, M, Schmidt, A, Schmittel   +3 more
openaire   +2 more sources

Bispecific antibodies for delivery into the brain

Current Opinion in Chemical Biology, 2013
The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J, Watts, Mark S, Dennis
openaire   +2 more sources

Bispecific antibody therapy for lymphoma

Best Practice & Research Clinical Haematology
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard, Gottfried, von Keudell   +1 more
openaire   +2 more sources

Immunotherapeutic potential of bispecific antibodies

Immunology Today, 1997
Abstract Bispecific antibodies (BsAbs) offer therapeutic potential by targeting tumors or pathogens as well as cytotoxic effector and/or antigen-presenting cells. A recent meeting ∗ ∗The Vth World Conference on Bispecific Antibodies was held at Volendam, The Netherlands, on 25–28 June 1997. focused on current issues in the BsAb field.
J G, van de Winkel, B, Bast, G C, de Gast   +2 more
openaire   +2 more sources

Bispecific antibodies in oncology

Nature Reviews Drug Discovery, 2022
Arman, Esfandiari, Sorcha, Cassidy, Rachel M, Webster   +2 more
openaire   +2 more sources

Strategies for the Generation of Bispecific Antibodies

ChemBioChem
Bispecific antibodies (BsAbs) are engineered immunoglobulins that can simultaneously recognize two distinct antigens or two distinct epitopes on the same antigen. They exhibit cooperative therapeutic effects surpassing those of natural monoclonal antibodies, such as bridging the immune cells and tumor cells to stimulate targeted immune response, or ...
Zhengyang Yuan, Xin Yang, Hanyu Jin, Susu Cui, Jia‐Bin Li   +4 more
openaire   +2 more sources

Chemical Production of Bispecific Antibodies

2004
This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Robert F, Graziano, Paul, Guptill
openaire   +2 more sources

Bispecific antibodies.

Critical reviews in immunology, 1993
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire   +1 more source

Bispecific antibodies in cancer therapy

Current Opinion in Immunology, 1999
Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources